Subchronic phencyclidine treatment impairs performance of C57BL/6 mice in the attentional set-shifting task

Behavioural Pharmacology

Volumn 15, Issue 2, 2004, Pages 141-148

  Laurent, V ^a   Podhorna, J ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Attentional set shift; Cognition; Mouse; Perseverance; Schizophrenia

Indexed keywords

PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FOLLOW UP; FOOD; HUMAN; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PERCEPTIVE DISCRIMINATION; PSYCHOMOTOR DISORDER; SCHIZOPHRENIA; STIMULUS; TASK PERFORMANCE; TRAINING;

ANIMALS; ATTENTION; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEEDING BEHAVIOR; HALLUCINOGENS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; ODORS; PHENCYCLIDINE; REWARD; SCHIZOPHRENIC PSYCHOLOGY;

EID: 2342612769     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200403000-00006     Document Type: Article

References (23)

1. Birrell JM, Brown VJ (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320-4324.
2. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B, et al. (2003). Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 160:700-719.
3. Colacicco G, Welzl H, Lipp HP, Wurbel H (2002). Attentional set-shifting in mice: modification of a rat paradigm, and evidence for strain-dependent variation. Behav Brain Res 132:95-102.
4. Drake RJ, Lewis SW (2003). Insight and neurocognition in schizophrenia. Schizophr Res 62:165-173.
5. Elliott R, McKenna PJ, Robbins TW, Sahakian BJ (1995). Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med 25:619-630.
6. Fox MT, Barense MD, Baxter MG (2003). Perceptual attentional set-shifting is impaired in rats with neurotoxic lesions of posterior parietal cortex. J Neurosci 23:676-681.
7. Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TR, Joyce EM (1998). Executive function in first-episode schizophrenia. Psychol Med 28:463-473.
8. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
9. Joyce E, Hutton S, Mutsatsa S, Gibbins H, Webb E, Paul S, et al. (2002). Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry Suppl 43:s38-s44.
10. 2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport 13:831-835.
11. Konradi C, Heckers S (2003). Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97: 153-179.
12. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
13. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
14. Lahti AC, Weiler MA, Tamara MB, Parwani A, Tamminga CA (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467.
15. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307.
16. Meador-Woodruff JH, Healy DJ (2000). Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31:288-294.
17. Mitchell RL, Elliott R, Woodruff PW (2001). fMRI and cognitive dysfunction in schizophrenia. Trends Cogn Sci 5:71-81.
18. Oades RD (1997). Stimulus dimension shifts in patients with schizophrenia, with and without paranoid hallucinatory symptoms, or obsessive compulsive disorder: strategies, blocking and monoamine status. Behav Brain Res 88:115-131.
19. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999). Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251-270.
20. Parellada E, Catarineu S, Catafau A, Bernardo M, Lomena F (2000). Psychopathology and Wisconsin card sorting test performance in young unmedicated schizophrenic patients. Psychopathology 33:14-18.
21. Rogers RD, Andrews TC, Grasby PM, Brooks DJ, Robbins TW (2000). Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans. J Cogn Neurosci 12:142-162.
22. Stratta P, Daneluzzo E, Bustini M, Prosperini P, Rossi A (2000). Processing of context information in schizophrenia: relation to clinical symptoms and WCST performance. Schizophr Res 44:57-67.
23. Yogev H, Hadar U, Gutman Y, Sirota P (2003). Perseveration and over-switching in schizophrenia. Schizophr Res 61:315-321.